BIOTECH ASSISTANT / FIELD NOTES

Thermodynamic model examines how HPMCAS stabilizes apparent nifedipine supersaturation

Academic source · AAPS Open

Source published: 2026-11-02

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

An AAPS Open study combined nifedipine solid-dispersion dissolution experiments with PC-SAFT phase diagrams. Predispersed HPMCAS-H delayed loss of filter-passing nifedipine, consistent with a predicted polymer-rich reservoir. The proposed colloidal phase lacked direct microscopy or light-scattering confirmation. Results concern one drug system, and filter-passing concentrations do not necessarily represent exclusively molecularly dissolved drug or improved clinical absorption.

Why this paper is included

Potential business implication: phase-diagram modeling may improve precipitation-inhibitor selection when paired with orthogonal measurements that distinguish molecular dissolution from colloidal drug carriage.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Formulation Development & Manufacturing Pharmaceutical solid state

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

XtalPi Asymchem WuXi AppTec / WuXi TIDES Porton Pharma Almac

Explore field companies →Explore literature →

Related updates

2026-11-06Journal of Pharmaceutical Health Care and Sciences

Crushed tadalafil formulation retains measured solid-state properties during a 90-day storage study

Japanese researchers evaluated crushed tadalafil tablets mixed with lactose at 40 mg/g during 90 days at 25°C under defined humidity and lighting conditions. Thermal analysis and powder X-ray diffraction showed no appreciable changes in thermal behavior or crystalline state. The findings concern the tested preparation and conditions; they do not establish clinical equivalence or a general storage period for other formulations.

Formulation Development & Manufacturing Pharmaceutical solid state Ask AI ↗

2026-11-05Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

Oligonucleotide Therapeutics & Delivery Formulation Development & Manufacturing Ask AI ↗

2026-11-05U.S. Food and Drug Administration

FDA grants accelerated approval for subcutaneous amivantamab combination in selected head and neck cancers

FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.

Formulation Development & Manufacturing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗